Combining Gene Expression Analysis of Gastric Cancer Cell Lines and Tumor Specimens to Identify Biomarkers for Anti-HER Therapies-the Role of HAS2, SHB and HBEGF

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 Mar 10

PMID 35264144

Authors

Karolin Ebert

Ivonne Haffner

Gwen Zwingenberger

Simone Keller

Elba Raimundez

Robert Geffers

Ralph Wirtz

Elena Barbaria

Vanessa Hollerieth

Rouven Arnold

Axel Walch

Jan Hasenauer

Dieter Maier

Florian Lordick

Birgit Luber

Affiliations

Soon will be listed here.

Abstract

Background: The standard treatment for patients with advanced HER2-positive gastric cancer is a combination of the antibody trastuzumab and platin-fluoropyrimidine chemotherapy. As some patients do not respond to trastuzumab therapy or develop resistance during treatment, the search for alternative treatment options and biomarkers to predict therapy response is the focus of research. We compared the efficacy of trastuzumab and other HER-targeting drugs such as cetuximab and afatinib. We also hypothesized that treatment-dependent regulation of a gene indicates its importance in response and that it can therefore be used as a biomarker for patient stratification.

Methods: A selection of gastric cancer cell lines (Hs746T, MKN1, MKN7 and NCI-N87) was treated with EGF, cetuximab, trastuzumab or afatinib for a period of 4 or 24 h. The effects of treatment on gene expression were measured by RNA sequencing and the resulting biomarker candidates were tested in an available cohort of gastric cancer patients from the VARIANZ trial or functionally analyzed in vitro.

Results: After treatment of the cell lines with afatinib, the highest number of regulated genes was observed, followed by cetuximab and trastuzumab. Although trastuzumab showed only relatively small effects on gene expression, BMF, HAS2 and SHB could be identified as candidate biomarkers for response to trastuzumab. Subsequent studies confirmed HAS2 and SHB as potential predictive markers for response to trastuzumab therapy in clinical samples from the VARIANZ trial. AREG, EREG and HBEGF were identified as candidate biomarkers for treatment with afatinib and cetuximab. Functional analysis confirmed that HBEGF is a resistance factor for cetuximab.

Conclusion: By confirming HAS2, SHB and HBEGF as biomarkers for anti-HER therapies, we provide evidence that the regulation of gene expression after treatment can be used for biomarker discovery.

Trial Registration: Clinical specimens of the VARIANZ study (NCT02305043) were used to test biomarker candidates.

Citing Articles

Systemic Therapy of Gastric Cancer-State of the Art and Future Perspectives.

Lordick F, Rha S, Muro K, Yong W, Obermannova R Cancers (Basel). 2024; 16(19).

PMID: 39409957 PMC: 11475804. DOI: 10.3390/cancers16193337.

Three possible diagnostic biomarkers for gastric cancer: miR-362-3p, miR-362-5p and miR-363-5p.

Hassanpour Aydinlou Z, Rajabi A, Emami A, Tayefeh-Gholami S, Teimourian S, Nargesi M Biomark Med. 2024; 18(10-12):567-579.

PMID: 39072355 PMC: 11364078. DOI: 10.1080/17520363.2024.2352419.

Obesity-Dependent Association of the rs10454142 with Breast Cancer.

Ponomarenko I, Pasenov K, Churnosova M, Sorokina I, Aristova I, Churnosov V Biomedicines. 2024; 12(4).

PMID: 38672173 PMC: 11048332. DOI: 10.3390/biomedicines12040818.

Quantitative proteomics profiling reveals the inhibition of trastuzumab antitumor efficacy by phosphorylated RPS6 in gastric carcinoma.

Hu C, Pei S, Wang J, Zu L, Shen W, Yuan L Cancer Chemother Pharmacol. 2023; 92(5):341-355.

PMID: 37507485 DOI: 10.1007/s00280-023-04571-2.

Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment.

Kwon H, Park Y, Nam S, Kang E, Kim K, Jeong I Cancer Med. 2023; 12(9):10371-10384.

PMID: 36916290 PMC: 10225221. DOI: 10.1002/cam4.5769.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Kauraniemi P, Hautaniemi S, Autio R, Astola J, Monni O, Elkahloun A . Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene. 2003; 23(4):1010-3. DOI: 10.1038/sj.onc.1207200. View

Kneissl J, Hartmann A, Pfarr N, Erlmeier F, Lorber T, Keller S . Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. J Cancer Res Clin Oncol. 2016; 143(4):573-600. PMC: 5352771. DOI: 10.1007/s00432-016-2308-z. View

Kunzke T, Balluff B, Feuchtinger A, Buck A, Langer R, Luber B . Native glycan fragments detected by MALDI-FT-ICR mass spectrometry imaging impact gastric cancer biology and patient outcome. Oncotarget. 2017; 8(40):68012-68025. PMC: 5620232. DOI: 10.18632/oncotarget.19137. View

Sanchez-Vega F, Hechtman J, Castel P, Ku G, Tuvy Y, Won H . and Amplifications Determine Response to HER2 Inhibition in -Amplified Esophagogastric Cancer. Cancer Discov. 2018; 9(2):199-209. PMC: 6368868. DOI: 10.1158/2159-8290.CD-18-0598. View

Keller S, Zwingenberger G, Ebert K, Hasenauer J, Wasmuth J, Maier D . Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines. Mol Oncol. 2018; 12(4):441-462. PMC: 5891041. DOI: 10.1002/1878-0261.12170. View

Kim J, Fox C, Peng S, Pusung M, Pectasides E, Matthee E . Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest. 2014; 124(12):5145-58. PMC: 4348950. DOI: 10.1172/JCI75200. View

Breyer J, Wirtz R, Otto W, Erben P, Kriegmair M, Stoehr R . In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Arch. 2017; 470(3):267-274. DOI: 10.1007/s00428-017-2064-8. View

Kneissl J, Keller S, Lorber T, Heindl S, Keller G, Drexler I . Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines. Int J Oncol. 2012; 41(2):733-44. DOI: 10.3892/ijo.2012.1479. View

10.

Haffner I, Schierle K, Raimundez E, Geier B, Maier D, Hasenauer J . HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study. J Clin Oncol. 2021; 39(13):1468-1478. PMC: 8099392. DOI: 10.1200/JCO.20.02761. View

11.

Sato S, Kamada H, Watanabe T, Tsuji I, Fan J . Identification of the cancer cell proliferation and survival functions of proHB-EGF by using an anti-HB-EGF antibody. PLoS One. 2013; 8(1):e54509. PMC: 3549951. DOI: 10.1371/journal.pone.0054509. View

12.

Lordick F, Kang Y, Chung H, Salman P, Oh S, Bodoky G . Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013; 14(6):490-9. DOI: 10.1016/S1470-2045(13)70102-5. View

13.

Lordick F, Janjigian Y . Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol. 2016; 13(6):348-60. PMC: 5521012. DOI: 10.1038/nrclinonc.2016.15. View

14.

Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y . Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res. 2002; 62(20):5813-7. View

15.

Apicella M, Corso S, Giordano S . Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget. 2017; 8(34):57654-57669. PMC: 5593674. DOI: 10.18632/oncotarget.14825. View

16.

Clynes R, Towers T, Presta L, Ravetch J . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-6. DOI: 10.1038/74704. View

17.

Boeckx C, Blockx L, Op de Beeck K, Limame R, Van Camp G, Peeters M . Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor. Am J Cancer Res. 2015; 5(6):1921-38. PMC: 4529614. View

18.

Ebert K, Zwingenberger G, Barbaria E, Keller S, Heck C, Arnold R . Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines. BMC Cancer. 2020; 20(1):1039. PMC: 7594334. DOI: 10.1186/s12885-020-07540-7. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Kumar S, Tomita Y, Wrin J, Bruhn M, Swalling A, Mohammed M . High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab. Clin Transl Oncol. 2016; 19(6):718-726. DOI: 10.1007/s12094-016-1596-8. View